Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

BACKGROUND: Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoni, M, De Giorgi, U, Iacovelli, R, Conti, A, Burattini, L, Rossi, L, Luca Burgio, S, Berardi, R, Muzzonigro, G, Cortesi, E, Amadori, D, Cascinu, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790174/
https://www.ncbi.nlm.nih.gov/pubmed/24008663
http://dx.doi.org/10.1038/bjc.2013.522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790174/
https://www.ncbi.nlm.nih.gov/pubmed/24008663
http://dx.doi.org/10.1038/bjc.2013.522

Ejemplares similares